CCCC
C4 Therapeutics, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
4.05
▲ 0.02 (0.53%)
MARKET · —
Price
Open
4.03
Prev close
4.03
Day high
4.10
Day low
3.94
Volume
1.16M
Market cap
—
P/E (TTM)
—
52W range
1.69 – 5.17
Trailing performance
Returnvs SPY
1W
-5.66%
-4.3%
1M
+9.59%
+5.9%
3M
+13.64%
+10.5%
6M
+85.19%
+74.1%
YTD
+109.42%
+97.1%
1Y
+53.85%
+33.8%
3Y
+20.85%
-53.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.04
+0.29% from price
SMA 20
3.81
+4.86% from price
SMA 50
3.93
+1.66% from price
SMA 100
3.58
+13.27% from price
SMA 200
2.97
+34.77% from price
EMA 12
3.99
+1.42% from price
EMA 26
3.90
+3.75% from price
EMA 50
3.82
+5.96% from price
RSI (14)
53.6
Neutral
MACD (12,26,9)
0.09
Hist 0.04
ATR (14)
0.23
5.78% of price
Realised vol 30D
56.8%
Annualised
Bollinger upper
4.35
20, 2σ
Bollinger lower
3.28
20, 2σ
50 / 200 cross
Golden
3.93 vs 2.97
Trend bias
Above 200
+34.77%
Risk profile
Beta vs SPY
2.02
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
56.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-52.1%
Peak to trough
Max drawdown 5Y
-97.8%
Peak to trough
ATR 14
0.23
5.78% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Zacks · 23h ago
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 11d ago
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · 11d ago
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 12d ago
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
Zacks · 46d ago
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
Zacks · 50d ago
C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?
Insider Monkey · 50d ago
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Zacks · 65d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.